Sarepta Inks $165M Myonexus Buy In Gene Therapy Deal
Massachusetts-based Sarepta Therapeutics said Wednesday it will snap up Myonexus and its budding pipeline for $165 million, making good on an exercise option in the latest industry bet on gene therapies....To view the full article, register now.
Already a subscriber? Click here to view full article